Health Canada approves MedMira’s Reveal® Rapid TP Test – Urgent New Tool In The Battle Against Syphilis

Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada. A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in […]
MedMira Announces Launch of Clinical Trial for Its Multiplo® TP/HIV Self-Test in Canada

Halifax, Nova Scotia, July 16, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira’s Multiplo® TP/HIV rapid test for use as a self-test in Canada. MedMira has been able to move forward with this label claim and avoid […]
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence

Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira’s Service-Disabled Veteran-Owned […]
MedMira Announces Partnership with MediGroup Physician Services in the United States

Halifax, Nova Scotia, 27th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partnership allows the Company to promote and sell its products to over 44,000 existing customers. MediGroup is the United States’s largest group purchasing organisations […]
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows MedMira to expedite its growth in the Canadian market with the recently Health Canada approved Multiplo® TP/HIV rapid antibody test and its Reveal® G4 HIV-1/2 rapid […]
MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications

Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional […]
MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test

Halifax, Nova Scotia, 9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led […]
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio […]
Corporate Update on Clinical Evaluation of MedMira’s Products

Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended […]
U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player […]